Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze ZVRA stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate ZVRA investment potential.

What is ZVRA stock price today?

Get real-time ZVRA stock price, historical data, and price charts on Financhill. Track ZVRA performance with our advanced analysis tools.

Is ZVRA a good investment?

Evaluate ZVRA investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy ZVRA stock?

To buy ZVRA stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of ZVRA?

View detailed market capitalization data and company valuation metrics for ZVRA on our comprehensive analysis page.

What is the P/E ratio of ZVRA?

Use our fundamental analysis tools to view ZVRA P/E ratio and compare valuation metrics with industry peers.

What are ZVRA earnings?

View ZVRA earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Zevra Therapeutics, Inc. Stock Predictions

Most Pre-IPO Big Tech Shifts Look Like This at the Start

*DISCLOSURE: This is a paid advertisement for Immersed Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.com

Sell

ZVRA
Zevra Therapeutics, Inc.

Last Price:

$8.60

Seasonality Move:

-4.54%

7 Day Trial

ALL ACCESS PASS

$ 7

This Critical Mineral's Up 122% in the Last 12 Months.

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at

Zevra Therapeutics, Inc. Stock Forecast

Over the next 52 weeks, Zevra Therapeutics, Inc. has on average historically fallen by 11.7% based on the past 10 years of stock performance.
Zevra Therapeutics, Inc. has fallen lower in 5 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
Is Zevra Therapeutics, Inc. Stock Undervalued?

The current Zevra Therapeutics, Inc. [ZVRA] share price is $8.60. The Score for ZVRA is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
ZVRA is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.

Will Zevra Therapeutics, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Zevra Therapeutics, Inc. has on average historically fallen by 11.7% based on the past 10 years of stock performance.

Zevra Therapeutics, Inc. Stock Rating

Sell

Zevra Therapeutics, Inc. (ZVRA) is a Sell

Is Zevra Therapeutics, Inc. overpriced?

Zevra Therapeutics, Inc. has fallen lower in 5 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

Zevra Therapeutics, Inc. Stock Price History

Is ZVRA stock going to rise?

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ZVRA is experiencing slight selling pressure.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Pharmaceuticals

Sector:

Health Care

Type:

stock

Website:

zevra.com

52-Week Data

52-Week High:

13.16

52-Week Low:

6.19

Prediction Charts

Market Cap:

484.2M

Price in USD:

8.60

Volume:

604.3K

Beta:

1.81

Technical Analysis

SMA50:

8.65

SMA100:

9.19

SMA200:

9.32

52-Wk Change:

9.14%

Stock Predictions

Is Zevra Therapeutics, Inc. stock public?

Yes, Zevra Therapeutics, Inc. is a publicly traded company.
What is the Zevra Therapeutics, Inc. stock quote today?

The Zevra Therapeutics, Inc. stock price is 8.60 USD today.
How to buy Zevra Therapeutics, Inc. stock online?

You can buy Zevra Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Jan-20	8.82	9.02	9.15	8.66
Jan-21	9.01	9.03	9.15	8.72
Jan-22	9.05	9.08	9.56	8.97
Jan-23	9.17	8.97	9.60	8.95
Jan-26	8.93	9.02	9.20	8.75
Jan-27	8.98	8.93	9.10	8.90
Jan-28	8.93	8.63	8.99	8.59
Jan-29	8.64	8.86	8.96	8.51
Jan-30	8.79	9.00	9.05	8.56
Feb-2	8.94	9.36	9.54	8.87
Feb-3	9.27	9.16	9.62	8.91
Feb-4	9.20	8.94	9.25	8.80
Feb-5	8.87	8.36	9.19	8.32
Feb-6	8.53	8.60	8.75	8.48

Zevra Therapeutics, Inc. Earnings

Zevra Therapeutics, Inc. Earnings Report: Per Share Zevra Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Zevra Therapeutics, Inc. Forecast Revenue Growth

Zevra Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Zevra Therapeutics, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings decrease this quarter of $0.19 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.54 per share, and an increase next year of $1.12 per share.

* Zevra Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.